Study Comparing Pulmonary Vein Isolation Alone Versus Combined With Substrate Modulation After Electric Cardioversion Fails in Adults With Persistent Atrial Fibrillation
Led by Elsan · Updated on 2024-04-24
450
Participants Needed
13
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
Atrial fibrillation AF is a common heart rhythm disorder characterized by irregular and rapid heart contractions. This research investigates whether electric cardioversion can help identify which patients with persistent AF need a pulmonary vein isolation PVI procedure alone or combined with substrate modulation. The study focuses on patients who have persistent AF, are symptomatic, and resistant to at least one anti-arrhythmic drug, including amiodarone.
All participants will first undergo electric cardioversion. Those with successful cardioversion will receive standard care following European Society of Cardiology ESC guidelines and be included in a registry. Participants whose cardioversion fails will be randomly assigned to receive either PVI alone or PVI combined with substrate modulation, which involves additional lesion creation to target affected heart areas.
Throughout the study, participants will be monitored for up to one year to assess the maintenance of sinus rhythm after ablation. Researchers will track procedure details, hospitalization duration, complications, and the need for further treatments or cardioversion. Outcomes will include the rate of sinus rhythm maintenance, procedure duration, and impact of heart tissue characteristics, with careful safety evaluations throughout the follow-up.
CONDITIONS
Brief Title
Pulmonary Vein Isolation Alone or in Combination With Substrate Modulation After Electric Cardioversion Failure
Research Team
A
Agustín Bortone, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Persistent atrial fibrillation continuous for at least 7 days, symptomatic and resistant to at least one anti-arrhythmic drug including amiodarone
Patient treated by electric cardioversion for persistent atrial fibrillation with planned ablation procedure within 4 to 6 weeks after cardioversion
Life expectancy greater than 5 years
Male or female aged between 18 and 80 years at the time of cardioversion
Affiliated to a health insurance system
Patient informed of the study and has signed informed consent
Patient with failed electric cardioversion confirmed by ECG, eligible for randomization prior to ablation
You will not qualify if you...
Current hyperthyroidism
Pregnant or breastfeeding women
Body Mass Index (BMI) greater than 35
Severe chronic obstructive pulmonary disease (COPD)
Hypertrophic heart disease
Mechanical or biological mitral valve
Contraindications to anticoagulants
Transient ischemic attack or stroke less than 6 months old
Psychiatric illness affecting follow-up
Left ventricular ejection fraction below 40%
Uncontrolled ischemic heart disease
Patients under legal protection
Previous cardiac surgery on left atrium
Active inflammatory conditions or diseases such as cancer or rheumatoid arthritis
Pulmonary embolism or phlebitis less than 6 months old
Prior atrial fibrillation ablation
Active cancer
Patient in sinus rhythm 4-6 weeks after cardioversion (included in registry, not randomized)
Complete absence of sinus rhythm after 3 cardioversion attempts (withdrawn from study)
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Procedure day and hospitalization up to 1 day
Participants undergo pulmonary vein isolation (PVI) alone or PVI combined with substrate modulation to treat persistent atrial fibrillation after failure of electric cardioversion.
1 procedure visit and hospitalization
Follow-up
Duration - Up to 1 year
Participants are monitored for up to 1 year after the ablation procedure to assess heart rhythm maintenance, complications, and treatment outcomes.
Multiple visits over 1 year for follow-up assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas Using the Globe Pulsed Field System to Treat Symptomatic Paroxysmal or Persistent Atrial Fibrillation
Evaluation of a Paddle-Shaped High-Density Multi-Electrode Catheter for Arrhythmia Mapping in Cardiac Patients
Study of Atrioventricular Junction Ablation versus Optimal Medication for Patients
With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation
Evaluating Combined Volt Pulsed Field Ablation and Amulet 2 Device for Atrial Fibrillation Treatment and Left Atrial Appendage Occlusion
Evaluation of the Sphere-9 Catheter and Affera Ablation System for Redo Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation
Study of Convergent Ablation with LARIAT Procedure Versus Standard Catheter Ablation for Persistent Atrial Fibrillation
Effect of Catheter Ablation and Antiarrhythmic Drugs on Cognitive Function in Patients Aged 60-80 with Mild Cognitive Impairment and Persistent Atrial Fibrillation
Evaluation of the CoreMap Electrophysiology Mapping System for Treating Persistent and Long-Standing Persistent Atrial Fibrillation
Multicenter Study Evaluating Novel Waveforms Delivered by the FARAPULSE Pulsed Field Ablation System for Treating Atrial Fibrillation
Study of Pulsed-field Ablation for Pulmonary Vein Isolation in Adults with Persistent Atrial Fibrillation Using Implantable Cardiac Monitors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
MARSHALL bundles elimination, Pulmonary veins isolation and Lines completion for ANatomical ablation of persistent atrial fibrillation: MARSHALL-PLAN case series.
Thomas Pambrun, Arnaud Denis, Josselin Duchateau...
Single-Procedure Outcomes and Quality-of-Life Improvement 12 Months Post-Cryoballoon Ablation in Persistent Atrial Fibrillation: Results From the Multicenter CRYO4PERSISTENT AF Trial.
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
Gerhard Hindricks, Tatjana Potpara, Nikolaos Dagres...
Marshall bundle elimination, Pulmonary vein isolation, and Line completion for ANatomical ablation of persistent atrial fibrillation (Marshall-PLAN): Prospective, single-center study.
Nicolas Derval, Josselin Duchateau, Arnaud Denis...